Evidence map›Paper›PMID 40508203›Full record

Observational studyInternational journal of molecular sciences2025

Is COVID-19 Coagulopathy a Thrombotic Microangiopathy? A Prospective, Observational Study.

Mauro Silingardi, Fulvia Zappulo, Ada Dormi, Attilia Maria Pizzini, Chiara Donadei, Maria Cappuccilli, Chiara Fantoni, Stefania Zaccaroni, Valeria Pizzuti, Nicola Cilloni and 5 more

Abstract readObservational Study
In one paragraph

Observational study in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Mauro SilingardiDepartment of Internal Medicine, Ospedale Maggiore "Carlo Alberto Pizzardi", 40133 Bologna, Italy.ORCID 0000-0003-2601-1579
Fulvia ZappuloNephrology, Dialysis and Kidney Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.ORCID 0000-0001-6041-2195
Ada DormiBiostatistics, Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum-University of Bologna, 40138 Bologna, Italy.
Attilia Maria PizziniDepartment of Internal Medicine, Ospedale Maggiore "Carlo Alberto Pizzardi", 40133 Bologna, Italy.
Chiara DonadeiDepartment of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum-University of Bologna, 40138 Bologna, Italy.ORCID 0000-0003-4864-3809
Maria CappuccilliDepartment of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum-University of Bologna, 40138 Bologna, Italy.
Chiara FantoniDepartment of Internal Medicine, Ospedale Maggiore "Carlo Alberto Pizzardi", 40133 Bologna, Italy.
Stefania ZaccaroniDepartment of Internal Medicine, Ospedale Maggiore "Carlo Alberto Pizzardi", 40133 Bologna, Italy.
Valeria PizzutiNephrology, Dialysis and Kidney Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.ORCID 0000-0002-5591-7663
Nicola CilloniDepartment of Anaesthesia, Intensive Care and EMS, Ospedale Maggiore "Carlo Alberto Pizzardi", 40133 Bologna, Italy.
Simona TantilloDepartment of Anaesthesia, Intensive Care and EMS, Ospedale Maggiore "Carlo Alberto Pizzardi", 40133 Bologna, Italy.
Antonella GuidiLaboratorio Unico Metropolitano, AUSL Bologna, 40133 Bologna, Italy.
Rita ManciniLaboratorio Unico Metropolitano, AUSL Bologna, 40133 Bologna, Italy.
Gaetano La MannaNephrology, Dialysis and Kidney Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.ORCID 0000-0001-5473-8551
Giorgia ComaiNephrology, Dialysis and Kidney Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.ORCID 0000-0003-4160-8840

Funding

Siemens NAThermofisher NAWerfen NA
6 · The paper itself

Abstract

Severe COVID-19 is often associated with coagulopathy and thrombotic complications. The underlying mechanisms are complex and multifactorial, involving platelet activation, dysregulation of the complement cascade, fibrinolytic imbalance, release of pro-inflammatory cytokines, immunothrombosis, antiphospholipid antibodies, and alterations in the von Willebrand factor (vWF)/ADAMTS13 axis. These pathways are also implicated in thrombotic microangiopathies (TMAs), characterized by endothelial injury and widespread microvascular thrombosis. In this prospective monocentric observational study, we investigated whether COVID-19-associated coagulopathy meets the criteria for TMA and evaluated the roles of complement activation and vWF/ADAMTS13 imbalance in disease severity. Forty-three hospitalized COVID-19 patients were enrolled and stratified by disease severity. Blood samples collected at admission were analyzed for hematologic, coagulation, inflammatory, and complement parameters. A 30-day follow-up recorded survival and thrombotic events. All patients showed elevated vWF and factor VIII levels; however, only vWF collagen-binding activity (vWF-CBA) significantly correlated with disease severity. ADAMTS13 activity remained above 60% in all cases, and no schistocytes were detected, arguing against a diagnosis of classical TMA. Nevertheless, the vWF-CBA/ADAMTS13 ratio was significantly higher in severe cases, particularly in unvaccinated individuals, suggesting endothelial dysregulation. Complement analysis revealed increased C5a levels and decreased C3b/iC3b ratios in severe disease, consistent with complement activation and consumption. C2 levels were also lower in these patients. Although complement activation and vWF/ADAMTS13 imbalance did not directly correlate, both pathways showed a similar trend according to disease severity. Overall, our findings indicate that COVID-19-related coagulopathy does not fulfill the criteria for classical TMA but shows features of complement-mediated endothelial injury and vWF dysregulation. The vWF-CBA may serve as a rapid, standardized tool for assessing endothelial dysfunction. Activation of the complement system, particularly via the lectin and alternative pathways, appears central to the prothrombotic state in severe COVID-19.

Indexed as

Blood Coagulation DisordersCOVID-19Thrombotic MicroangiopathiesADAMTS13 ProteinAdultAgedComplement ActivationFemaleHumansMaleMiddle AgedProspective StudiesSARS-CoV-2Severity of Illness Indexvon Willebrand FactorADAMTS13 ProteinADAMTS13 protein, humanvon Willebrand FactorADAMTS13complement activationCOVID-19-associated coagulopathyinflammatory cytokinesvon Willebrand factor

Identifiers

PMID40508203
PMCPMC12155441

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.